Acetylated carnitine compound · Fact sheet
Acetyl-L-carnitine
Also known as ALCAR · Acetylcarnitine
Acetyl-L-carnitine is an acetylated carnitine form studied in neurologic disease. A large chemotherapy trial found worse neuropathy at 24 weeks, and a year-long Alzheimer trial did not slow decline overall.
What is Acetyl-L-carnitine?
It is related to L-carnitine but is not interchangeable with prescription levocarnitine for carnitine deficiency.
Changes in energy metabolism do not establish broad neuroprotection.
Benefits & claims
Interest in Acetyl-L-carnitine spans cognition and sleep, aging and energy, specific medical conditions. Study findings apply to the named formulation and population.
What the evidence supports
- The 409-evaluable-patient chemotherapy study found no benefit at 12 weeks and worse neuropathy at 24 weeks.
- The 229-person Alzheimer study did not improve its primary intention-to-treat outcomes.
- Other condition-specific studies cannot justify calling ALCAR a general nerve-protective supplement.
Research areas
- Formulation-specific human outcomes
- Mechanistic research
Dosage & frequency
Human study contextThis is an exposure from a named human study, not a generally established treatment or enhancement regimen.
Taxane-neuropathy prevention trial
Women receiving adjuvant taxane-based breast-cancer chemotherapy; 409 evaluable
- Amount
- 3,000 mg total daily
- Frequency
- Daily for 24 weeks
- Route studied or labeled
- Oral
This is a harm-context reference: neuropathy was worse by week 24. It does not support prevention of chemotherapy neuropathy or a wellness regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- It is related to L-carnitine but is not interchangeable with prescription levocarnitine for carnitine deficiency.
Formulation differences
- Changes in energy metabolism do not establish broad neuroprotection.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Side effects & risks
- Worsened taxane-related neuropathy is a clinically important harm in the studied cancer population.
- Carnitine-related supplements can cause gastrointestinal symptoms and have unresolved formulation-specific interactions.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceControlled human findings depend on population. The chemotherapy and early-onset Alzheimer studies directly limit broad nerve-protection and cognition claims.
Studies
24-week randomized taxane-chemotherapy study; neuropathy worsened.
One-year early-onset Alzheimer trial; primary outcomes negative.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved Acetyl-L-carnitine drug indication is established for the supplement uses discussed here. Supplement availability is not FDA approval of efficacy or safety.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reproducibility in larger independent trials
- Long-term outcomes and adverse effects
- Equivalence of different preparations and interaction profiles
Summary
Other condition-specific studies cannot justify calling ALCAR a general nerve-protective supplement.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedRandomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
24-week randomized taxane-chemotherapy study; neuropathy worsened.
- pubmedA 1-year controlled trial of acetyl-l-carnitine in early-onset AD.
One-year early-onset Alzheimer trial; primary outcomes negative.
- nihNIH ODS: carnitine
Formulation differences, adverse effects and limits of supplementation evidence.